	US 12,357,680 B2
	Inhibition of histone methyl transferases to treat cancer
Roland Schüle, Weisweil (DE); Eric Metzger, Algolsheim (FR); Sheng Wang, Freiburg (DE); Manfred Jung, Gundelfingen (DE); Nicolas Barthes, Blodelsheim (FR); Bernhard Breit, Gundelfingen (DE); Daad Sarraf, Freiburg (DE); and Tabea Pappert, Harxheim (DE)
Assigned to Albert-Ludwigs-Universitat Freiburg, Freiburg (DE)
Appl. No. 17/277,183
Filed by Albert-Ludwigs-Universitat Freiburg, Freiburg (DE)
PCT Filed Sep. 18, 2019, PCT No. PCT/EP2019/075062 § 371(c)(1), (2) Date Mar. 17, 2021, PCT Pub. No. WO2020/058358, PCT Pub. Date Mar. 26, 2020.
Claims priority of application No. 18195101 (EP), filed on Sep. 18, 2018.
Prior Publication US 2022/0184195 A1, Jun. 16, 2022
Int. Cl. A61K 39/00 (2006.01); A61K 31/437 (2006.01); A61K 31/519 (2006.01); A61K 31/7076 (2006.01); A61K 31/7105 (2006.01); A61P 35/00 (2006.01); C07K 16/40 (2006.01); C12N 9/10 (2006.01); C12N 15/113 (2010.01)

CPC A61K 39/001154 (2018.08) [A61K 31/437 (2013.01); A61K 31/519 (2013.01); A61K 31/7076 (2013.01); A61K 31/7105 (2013.01); A61P 35/00 (2018.01); C07K 16/40 (2013.01); C12N 9/1007 (2013.01); C12N 15/1137 (2013.01); A61K 2039/505 (2013.01); C12N 2310/14 (2013.01)]

2 Claims

1. A method for treating cancer in a subject, wherein said method comprises administering a KMT9-inhibitor to the subject, wherein said KMT9-inhibitor is a selective KMT9-inhibitor, wherein said KMT9-inhibitor is a small molecule selective for KMT9-inhibition, and wherein the small molecule selective for KMT9-inhibition has the following structure:

2. A method for treating cancer in a subject, wherein said method comprises administering a KMT9-inhibitor to the subject, wherein said KMT9-inhibitor is a selective KMT9-inhibitor, wherein said KMT9-inhibitor is a small molecule selective for KMT9-inhibition, and wherein the small molecule selective for KMT9-inhibition has the following structure: